LOX and osteosarcoma: Moreover, LOX inhibitor β-aminopropionitrile (BAPN) could effectively suppress osteosarcoma migration and promote apoptosis, and targeting LOX in CAFs in this way has demonstrated promising efficacy in treatment of recurrent osteosarcoma (83).